Exousia Pro Will Launch a Web Series with Our New Consultant

Rhea-AI Summary

Exousia Pro announces the addition of Dr. Marvin Hausman as a consultant and the launch of a new weekly web series titled "Ask Dr. Hausman." The clinical-stage biotech company, trading as MAJI on OTCPINK, focuses on developing exosome-based therapies for cancer and other diseases.

Dr. Hausman, who played a key role in creating Exousia AI and establishing the Glioblastoma study with UCF, will host the series where shareholders can submit questions. The program will cover updates on ongoing studies, FDA submissions, and future IND trials.

Company President Matt Dwyer highlighted Dr. Hausman's valuable network of scientific and financial professionals in the biotech sector, expressing confidence that this collaboration will open new opportunities for Exousia Pro's advancement in plant-based exosome therapies.

Positive

• Strategic addition of Dr. Marvin Hausman as consultant strengthens scientific leadership
• Dr. Hausman brings valuable biotech industry connections and network access
• Company advancing in clinical-stage biotech with focus on exosome therapies for cancer treatment
• Ongoing Glioblastoma study partnership with UCF indicates research progress
• Weekly web series launch improves shareholder communication and transparency

Negative

• Consultant contract still being finalized, indicating uncertainty in engagement terms
• Early clinical stage company with no approved products yet
• No mention of financial terms or compensation for the consultant

Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.

ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is launching a weekly web series titled "Ask Dr. Hausman."

Our chief science officer, Dr. Marvin Hausman, will join Exousia Pro as a consultant; his contract is being finalized now. Dr. Hausman was instrumental in creating Exousia AI and establishing the Glioblastoma study with UCF, and will assist Exousia Pro in advancing therapies using our plant-based exosomes. Exousia Pro will launch a new web series, "Ask Dr. Hausman." Shareholders will be able to email questions that Dr. Hausman will answer weekly. Dr. Hausman will also share updates on various studies conducted, our FDA submissions, and future IND trials.

Matt Dwyer, our President, stated, "Exousia Pro is very fortunate to have Dr. Hausman working with us. His rolodex of scientific and financial professionals in the biotech world is priceless. We believe that Dr. Hausman can open doors for Exousia Pro that we could never do. I met Marvin about 1 year ago and have established a strong relationship with him, and I look forward to working closely with him in advancing Exousia Pro."

About Us

Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.

For more information, please visit: www.exousiapro.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Marijuana Inc.

View the original press release on ACCESS Newswire

FAQ

Who is Dr. Marvin Hausman joining at Exousia Pro (MAJI) in 2025?

Dr. Marvin Hausman is joining Exousia Pro (MAJI) as a consultant in 2025 and will host a weekly web series called 'Ask Dr. Hausman' where he will answer shareholder questions and provide updates on studies, FDA submissions, and IND trials.

What is the new web series 'Ask Dr. Hausman' by Exousia Pro (MAJI)?

Ask Dr. Hausman is a weekly web series where shareholders can email questions for Dr. Hausman to answer. He will also provide updates on ongoing studies, FDA submissions, and future IND trials.

What role did Dr. Hausman play in Exousia Pro's Glioblastoma study?

Dr. Hausman was instrumental in creating Exousia AI and establishing the Glioblastoma study with UCF. He will now help advance therapies using plant-based exosomes at Exousia Pro.

How will Dr. Hausman benefit Exousia Pro (MAJI) as a consultant?

According to President Matt Dwyer, Dr. Hausman brings valuable connections to scientific and financial professionals in the biotech world, which could open new opportunities for Exousia Pro that were previously inaccessible.

What type of treatments is Exousia Pro (MAJI) developing?

Exousia Pro is a clinical-stage biotech company developing therapies using exosomes for the treatment of cancer and other diseases, with a focus on plant-based exosomes.